Error message
Notice: Undefined index: content in _drupal_default_html_head() (line 345 of /var/www/vhosts/rovi.es/httpdocs/includes/common.inc).
|
Date |
Title |
Description |
PDF |
|
10 May 2023 |
On P&L |
The Company releases the first quarter 2023 financial results presentation
|
Download |
|
10 May 2023 |
On P&L |
The Company releases the press release related to the first quarter 2023 financial results
|
Download |
|
25 Apr 2023 |
On business and financial situation |
ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE)
|
Download |
|
21 Feb 2023 |
On business and financial situation |
The Company releases the full year 2022 financial results presentation.
|
Download |
|
21 Feb 2023 |
On business and financial situation |
The Company releases the press release related to the full year 2022 financial results.
|
Download |
Pages
|
Date |
Title |
Description |
PDF |
|
09 Jan 2023 |
Liquidity and counterparty agreements |
Liquidity contract: transactions conducted in the fourth quarter of 2022
|
Download |
|
15 Dec 2022 |
On Corporate Governance |
The Company informs about changes in the Board of Directors and the creation of an Advisory Committee.
|
Download |
|
04 Oct 2022 |
On business and financial situation |
The Company informs that it has signed a joint venture agreement with Càrniques Ceirà and Grupo Costa to construct a plant for the production of compounds of high technological value.
|
Download |
|
03 Oct 2022 |
Liquidity and counterparty agreements |
Liquidity contract: transactions conducted in the third quarter of 2022
|
Download |
|
29 Jul 2022 |
Other relevant información |
On 26 July 2022 the public deed relating to the Company’s share capital decrease was registered with the Commercial Registry of Madrid.
|
Download |
Pages
|
Date |
Title |
Description |
PDF |
|
04 Apr 2019 |
Liquidity contracts and specialists |
Liquidity contract: transactions conducted in the first quarter of 2019
|
Download |
|
19 Mar 2019 |
R&D: new licenses, patents and registered trademarks |
ROVI Announces Positive Topline Results from Phase 3 study of Doria® in Patients with Schizophrenia
|
Download |
|
26 Feb 2019 |
Informe Anual de Remuneraciones de los Consejeros |
ROVI releases the 2018 annual report regarding remuneration of the members of the Board of Directors
|
Download |
|
26 Feb 2019 |
Informe Anual de Gobierno Corporativo |
ROVI releases the 2018 Annual Corporate Governance Report
|
Download |
|
26 Feb 2019 |
Otros sobre gobierno corporativo |
The Company informs about the agreements adopted by the Board of Directors
|
Download |
Pages
